Content continues after advertisement

Research Note: New Findings May Help Dogs with Chronic Enteropathy

Internal Medicine

October 2021

Sign in to Print/View PDF

This study examined biopsies from 12 dogs diagnosed with chronic inflammatory enteropathy (CIE) to quantify expression of the GI receptor for advanced glycation end products (RAGE), a pattern recognition receptor of the innate immune system. These biopsies were compared with expression from biopsies of 9 healthy dogs. Epithelial RAGE expression in the duodenum, ileum, and colon was higher in dogs with CIE, and several histologic and inflammatory lesion criteria as well as markers of inflammation (ie, serum C-reactive protein, fecal calprotectin concentration) were related to epithelial RAGE expression in these intestinal structures. These findings suggest that transmembrane RAGE expression and intracellular RAGE signaling are involved in the chronic inflammatory response of dogs with CIE. RAGE antagonization may present a novel therapeutic intervention for chronic GI inflammation.


For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.


Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy